Corneal Epithelial Immune Dendritic Cell Alterations in Subtypes of Dry Eye Disease: A Pilot In Vivo Confocal Microscopic Study

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
10.1167/iovs.15-17433

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34917359

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Dry eye disease (DED) is one of the most commonly encountered ophthalmic disorders. It is a multifactorial disease of the ocular surface and tear film, characterized by symptoms of eye irritation, tear instability, and vision impairment. In addition to evaluating symptoms, a variety of clinical tests are currently being used to diagnose DED, including the Schirmer’s wetting test, tear break-up time (TBUT), tear osmolarity, and vital dye staining of the ocular surface by fluorescein, Rose Bengal and Lissamine Green. However, clinical tests are currently being used to diagnose DED, including aqueous-deficient, evaporative, and a combination of both. A significant need for objective tests, which can be used to accurately diagnose DED and/or monitor therapeutic response, has been demonstrated in clinical trials. Keywords: dry eye disease, in vivo confocal microscopy, inflammation, dendritic cells.

To evaluate density and morphology of corneal epithelial immune dendritic cells (DCs) in different subtypes of dry eye disease (DED) using in vivo confocal microscopy (IVCM).

This retrospective study included 59 eyes of 37 patients with DED and 40 eyes of 20 age-matched healthy controls. Based on clinical tests, eyes with DED were categorized into two subtypes: aqueous-deficient (n = 35) and evaporative (n = 24). For all subjects, images of laser scanning in vivo confocal microscopy (IVCM) of the central cornea were analyzed for DC density, DC size, number of dendrites, and DC field. These DC parameters were compared among all dry eye and control groups.

The control groups compared with the controls, patients with DED had significantly higher DC density, larger DC size, higher number of dendrites, and larger DC field (all P < 0.001). Comparison between aqueous-deficient and evaporative subtypes demonstrated that DC density was significantly higher in aqueous-deficient subtype (189.8 ± 36.9 vs. 58.9 ± 9.4 cells/mm², P = 0.001). However, there were no significant differences in morphologic parameters between DED subtypes. When aqueous-deficient DED with underlying systemic immune disease (Sjögren’s syndrome and graft versus host disease) were compared with nonimmune conditions, the immunologic subgroup showed significantly higher DC density, DC size, and number of dendrites (all P < 0.05).

Corneal IVCM demonstrated differential changes in DC density and morphologic DC parameters between subtypes of DED. These changes, which reflect the degree of immune activation and inflammation in DED, can be used for clinical practice and endpoints in clinical trials.

Keywords: dry eye disease, in vivo confocal microscopy, inflammation, dendritic cells.
Further, while previous studies have revealed changes in DC density, morphologic changes of DC have recently gained attention, as increased size of DCs is a sign of their maturation, activation, MHC-II (HLA-DR) expression, and their antigen presentation capability. Thus, recent studies have assessed DC morphology in their evaluation of IVCM changes of the cornea in conditions other than DED.

As the level of corneal immune cell activation may vary in different subtypes of DED (aqueous-deficient versus evaporative), we hypothesize that patients with different subtypes of DED will demonstrate differential levels of DC changes not only for DC density, but also for DC morphology.

**Materials and Methods**

This retrospective, cross-sectional, controlled study included 59 eyes of 37 patients with DED and 40 eyes of 20 age-matched healthy controls. The charts and IVCM images were reviewed for these individuals who had been seen in the Cornea Service of the Massachusetts Eye & Ear Infirmary, Boston, Massachusetts between 2009 and 2012. The protocol of the study was approved by the institutional review board/Ethics Committee, complied with the Health Insurance Portability and Accountability Act (HIPAA) and adhered to the tenets of the Declaration of Helsinki.

All these patients had typical symptoms of DED for a duration of 6 months or more. The patients were categorized to have evaporative DED if they had TBUT less than 10 seconds and Schirmer’s test results greater than 5 mm. In the presence of a low Schirmer’s test result (≤5 mm) and a low TBUT (<10 seconds), the patient was categorized as aqueous-deficient DED. The aqueous-deficient DED group was further stratified into two subgroups, the immunologic subgroup (including cases with Sjögren’s syndrome, as defined by American-European consensus group criteria) and the nonimmunologic subgroup. The healthy controls were asymptomatic healthy individuals with a clear healthy cornea without vital staining and normal tear function tests. The exclusion criteria in both groups included active ocular allergy, history of contact lens wear or infectious keratitis in the past 3 months, history of refractive surgery, history of intraocular surgery, or diabetes mellitus.

**In Vivo Confocal Microscopy**

All patients in both the DED and control groups had undergone imaging with a laser IVCM of the central cornea using Heidelberg Retina Tomograph 3 with the Rostock Cornea Module (Heidelberg Engineering GmbH, Heidelberg, Germany) as previously described. This microscope is equipped with a ×65 objective immersion lens with a numerical aperture of 0.9 (Olympus, Tokyo, Japan) and uses a 670-nm red wavelength diode laser source. Each image represents a coronal section of the cornea of 400 × 400 μm (horizontal × vertical). Digital images were recorded with the sequence mode at a rate of 3 frames per second, including 100 images per sequence. There was a separation of 1 μm between adjacent images, and a lateral resolution of 1 μm/pixel. A total of six to eight sequence scans of nonoverlapping areas were recorded from the full thickness of the central cornea, with three to four sequence scans focusing on the subbasal layer, resulting in 300 to 400 images of the subbasal layer alone.

**Image Analysis**

For each eye, three images of epithelial DCs, posterior to the basal epithelial layer and anterior to Bowman’s layer, typically at a depth of 50 to 70 μm were chosen for analysis. The criteria to select the images were the best focused, without motion or folds, best contrast, and representing a single layer of the cornea. Dendritic cells were morphologically identified as bright individual dendritiform structures with cell bodies. The following parameters were determined for each image, as elaborated below: DC density, DC size (the area covered by the body of the cell), number of dendrites per DC, and DC field (area bounded within the span of the dendrites).

To evaluate the density and morphologic parameters of DC in IVCM images, ImageJ software (http://imagej.nih.gov/ij/; provided in the public domain by the National Institutes of Health, Bethesda, MD, USA) was used. The density of DC per image was counted using Cell Count tool in the manual mode. All complete DCs present in each image, as well as partial cells on the top and right borders of each frame were counted. The average density of DCs for three images was then calculated. The 10 most representative cells in three images for each eye were then selected for morphologic analysis. The size of DC was measured using the Threshold Function (Fig. 1A). The number of dendrites per cell was calculated manually. The DC field, which is a representative of the cell span and the length of the dendritic processes, was calculated by measuring the area covered by a polygon joining the dendrite tips around each cell (Fig. 1B). Two masked observers (RRD and AC) evaluated all the images and the averaged values were used for the analysis. In case of more than 10% difference between the two observers, a third observer evaluated the images as well and the average of these three values was used for the analysis.

**Statistical Analysis**

The normal distribution of the data was first confirmed with the Shapiro-Wilk test. Comparison of various clinical and IVCM parameters among different groups were performed using Student’s t-test and ANOVA with post hoc Bonferroni test. P values less than 0.05 were considered as statistically significant. The IVCM data were expressed as mean ± SEM. The differences found in DC density (the primary endpoint) between the evaporative and aqueous-deficient subtypes were used to calculate the power of the study to detect a statistically significant difference, which was 95%.

**Results**

This study included 59 eyes of 37 patients with DED (28 females and 9 males) and 40 eyes of 20 healthy controls (14 females and 6 males). The mean age was 58.1 ± 17.4 years.
(range, 24-87 years) in the DED group and 57.9 ± 7.6 years (range, 48-74 years) in the control group (P = 0.93). The subtypes of DED included, evaporative in 24 eyes, and aqueous-deficient in 35 eyes. The demographic data of these subtypes have been presented in Table 1.

Compared with the control group, the eyes in the DED group had a higher DC density (19.6 ± 2.8 vs. 136.5 ± 23.6 cells/mm², respectively, P < 0.001, with an average increase of 700%), larger DC size (54.2 ± 1.7 vs. 144.6 ± 14.8 μm², respectively, P < 0.001, with an average increase of 266%), higher number of dendrites per cell (2.2 ± 0.04 vs. 4.4 ± 0.1, respectively, P < 0.001, with an average increase of 200%), and larger DC field (198.0 ± 8.6 vs. 414.7 ± 55.3 μm², respectively, P < 0.001, with an average increase of 209%; Fig. 2). Table 2 shows the IVCM parameters for DCs in subtypes of DED as compared with the control group. In the aqueous-deficient subtype, DC density and all morphologic parameters (DC size, number of dendrites, and DC field) were significantly higher than the control group (all P < 0.001), with average increases of 968%, 284%, 200%, and 224%, respectively. In the evaporative subtype, density of DC as well as DC size and number of dendrites were significantly higher than in the control group (P < 0.001, P = 0.02, and P < 0.001, respectively) with average increases of 300%, 242%, and 191%, respectively. However, the difference in DC field between the evaporative subtype and the control group was not statistically significant (P = 0.13), even though there was an average increase of 188%.

Comparison between the aqueous-deficient and evaporative subtypes demonstrated that although DC density was significantly higher in the aqueous-deficient subtype (189.8 ± 36.9 vs. 58.9 ± 9.4 cells/mm², P = 0.001), there were no significant differences in the morphologic parameters between the two subtypes (Fig. 3).

The aqueous-deficient DED group was further stratified into two subgroups, the immunologic subgroup (n = 16) and nonimmunologic subgroup (n = 19). The IVCM parameters for DCs for these subgroups have been compared with the evaporative subtype in Table 3. The DC density, DC size, and number of dendrites, but not DC field, were significantly higher in the immunologic subgroup as compared with the nonimmunologic subgroup (P = 0.004, P = 0.04, P = 0.04, P = 0.15, respectively; Fig. 4). Further, comparison of these two subgroups with the evaporative subtype showed that although there were no significant differences in any IVCM parameters between the nonimmunologic subgroup and the evaporative subtype, the immunologic subgroup had significantly higher DC density than the evaporative subtype (P = 0.002; Fig. 4).

**DISCUSSION**

The current study showed that in patients with DED there were significant increases, not only in DC density, but also in all morphologic DC parameters, including cell size, number of dendrites, and cell field. Furthermore, DC density was significantly lower in the evaporative subtype of DED as compared with the aqueous-deficient subtype, suggesting lower degrees of immune activation or inflammation in this subtype of DED. Increased DC activation with higher DC density and larger cells with more dendrites were also noted in cases with underlying systemic autoimmune diseases, such as GVHD and Sjögren’s syndrome, as compared with patients with nonimmunologic diseases. These data collectively implicate the utility of IVCM in revealing the underlying immune cell changes in subtypes of DED. 26

Corneal epithelial immune DCs, including Langerhans cells, are professional antigen-presenting cells, which play a significant role in corneal immune homeostasis. Not only do they have an important role in innate immunity, but they also are major players in the immune surveillance and induction of...
antigen-specific immune reactivity and tolerance. Given their established role in immune regulation of the ocular surface, there has been a recent interest in evaluation of their alterations in various ocular surface diseases. Recent studies have shown that the DC density significantly increases in various conditions such as DED, corneal graft rejection, contact lens wear, and infectious keratitis. In addition to changes in DC density, the morphology of these cells changes upon stimulation, resulting in maturation of these cells with an increase in cell size and formation and lengthening of dendritic processes. Evaluation of DC in the clinical setting has recently been facilitated by the fact that they can be easily detected and quantified by laser IVCM, with high interobserver agreement in their quantification. Using IVCM, although our control group had a DC density within the range reported before, the DED group showed a significantly higher DC density compared with the age-matched controls. Furthermore, using a detailed morphologic description of DCs, we demonstrated that in DED these immune cells had a larger cell size with increased number and length of dendrites. The average increase in DC size, number of dendrites, and DC field as compared with controls were 266%, 200%, and 209%, respectively. Increased DC size and number of dendrites in DED has also been reported previously using qualitative scales. However, because DED is a heterogeneous disease with multiple underlying etiologies, we further evaluated the DC changes in subtypes of the disease. In our study, the evaporative and aqueous-deficient subtypes demonstrated differential degrees of increased DC parameters (Table 2; Fig. 3). Compared with the controls, eyes with both aqueous-deficient and evaporative subtypes had significant increases in DC density and all morphologic parameters, except for DC field in the evaporative subtype. For the aqueous-deficient and evaporative subtypes, there were mean increases of 968% and 300%, respectively, for DC density, 284% and 242%, for DC size, 200% and 191% for number of dendrites, and 224% and 188% for DC field. Furthermore,
comparison of these two subtypes of DED revealed that although DC density and all morphologic parameters were higher in the aqueous-deficient subtype, the difference reached a statistical significance only for the DC density ($P = 0.001$), but not morphologic parameters (Fig. 3). Therefore, although corneal immune changes are seen in both subtypes of DED, the extent of involvement seems to be dependent on the subtype and is more severe in aqueous-deficient eyes. However, because the aqueous-deficient DED itself may be associated with underlying systemic immune diseases, we further investigated the DC alterations in these systemic conditions. The current study further subdivided eyes with aqueous-deficient DED into two subgroups: with and without underlying systemic immunologic disease such as Sjögren’s syndrome and GVHD (Table 3). Interestingly, DC density and morphologic parameters, except for DC field, were significantly higher in eyes with these underlying immunologic conditions (Fig. 4). This is in line with previous data, where increased DC density in eyes with Sjögren’s syndrome compared with non-Sjögren’s DED has been described.19 Furthermore, Lin et al.18 found that although DC density and size increased in the central cornea of DED with and without Sjögren’s syndrome, peripheral corneas demonstrated higher DC density and larger DC size only in patients with Sjögren’s syndrome. In addition, increased DC density in the cornea and conjunctiva of patients with Sjögren’s syndrome compared with non-Sjögren’s DED was demonstrated by Wakamatsu and coworkers.50 Moreover, although changes in corneal DC parameters have not been previously reported in GVHD, an increased DC density has previously been noted in patients with systemic autoimmune diseases such rheumatoid arthritis, ankylosing spondylitis, and Stevens-Johnson syndrome.20,21,59 Visibility of these immune changes in the cornea may make it possible to assess the activity of immune system and the inflammatory response, and thus help tailor treatment through patient stratification. Interestingly, Villani and colleagues40 recently showed that in patients who had active rheumatoid arthritis with secondary Sjögren’s syndrome, systemic immunosuppression resulted in a significant decrease in corneal DC density, which paralleled the improvement in the ocular symptoms and signs. This further implicates the use of corneal DC parameters to evaluate the efficacy anti-inflammatory therapy for DED in clinical practice and clinical trials. Therefore, this approach may be used as a biomarker in clinical research to evaluate the degree of corneal inflammation in DED and to monitor the therapeutic effect of anti-inflammatory drugs.41

Despite demonstrating the utility of DC parameters in subtypes of DED, our current study has several limitations. First of all, although in the Dry Eye Workshop 2007 (DEWS) DED has been divided into aqueous-deficient and evaporative subtypes, the criteria for the distinction between these two have not been clarified by this Workshop.1 Therefore, since the TBUT was less than 10 seconds in all patients, we have used the Schirmer’s test, which is commonly used to measure tear secretion, to categorize the patients into these two subtypes. Our aqueous-deficient subtype in fact had both low Schirmer’s test values and low TBUT. Eyes with pure aqueous tear deficiency (normal TBUT) were not included in this study, as this subtype is not commonly encountered. Furthermore, because of the retrospective nature of the study, we could not use any established questionnaire to diagnose the DED; in addition, we did not evaluate the tear film quality in our patients. In addition, we did not investigate the effects of DED severity on the DC density and morphology in different subtypes, as it would require a much larger sample size. Moreover, only the central part of the cornea was evaluated in the current study, and thus the results cannot be extrapolated to the peripheral cornea or the conjunctiva. Previous studies have shown that changes in the central and peripheral cornea in DED may not necessarily parallel each other.16 Nevertheless, our study
provides, for the first time, a detailed quantitative description of DC morphologic parameters for IVCM images in patients with subtypes of DED, which may aid in the improved assessment of these cells. Thus, the demonstration of differential responses in DC parameters in different subtypes of DED may further elucidate the pathogenesis of this complex disease. While the current study was designed and powered to assess DC density and morphologic features in subtypes of DED, currently a study in a larger cohort of patients with DED is underway to assess the correlation of these DC changes to severity if DED.

In conclusion, there are differential changes in both DC density and morphologic DC parameters between subtypes of DED. These changes, which reflect the degree of immune activation and inflammation in DED, can be detected and quantified objectively by corneal IVCM, allowing its use for clinical practice and clinical trials.

Acknowledgments

Supported by grants from the National Institutes of Health (Bethesda, MD, USA) K08-EY020575 (PH), New England Corneal Transplant Research Fund (PH; Boston, MA, USA), Falk Medical Research Foundation (PH; Chicago, IL, USA), and Research to Prevent Blindness (PH, RD; New York, NY, USA).

Disclosure: A. Kheirkhah, None; R. Rahimi Darabad, None; A. Cruzat, P; A.R. Hajrasouliha, None; D. Witkin, None; N. Wong, None; R. Dana, Allergan (C), P; P. Hamrakh, Allergan (C), GlaxoSmithKline (C), P

References


